Literature

Search Literature

You can search and request for digital copy(ies) of literature listed below. Your request will be processed within 5-10 business days. (You need to log in to request literature copies.) To read the abstracts, click on the DOI Link button.

Keyword

Filter by Protein Type

Filter by Contents

Filter by Products

You need to log in to request literature copies.

Select the literature you wish to request a copy of. To read the abstracts, click on teh DOI Link button.

41 Results Found

  1. 10
  2. 20
  3. 30
  4. All

  1. Development of small-scale models to understand the impact of continuous downstream bioprocessing on integrated virus filtration

    DOI Link
    Author
    Scott Lute, Julie Kozaili, et al.
    		 Organization
    U.S. FDA, Asahi Kasei Medical Co., Ltd.
    Journal
    Biotechnol Progress
    		 Year
    2020
    Access
    Open

  2. Microscopic visualization of virus removal by dedicated filters used in biopharmaceutical processing: Impact of membrane structure and localization of captured virus particles

    DOI Link
    Author
    Adan-Kubo, J., et al.
    		Organization
    Japanese Blood Products Organization, Asahi Kasei Medical Co., Ltd.
    Journal
    Biotechnol Progress.2019;35:e2875
    		 Year
    2019
    Access
    Open

  3. The Role of Nanofiltration in the Pathogen Safety of Biologicals: An Update

    DOI Link
    Author
    Inouye, M. and Burnouf, T.
    		 Organization
    M.I.: Asahi Kasei Medical Co., Ltd., T.B.: Taipei Medical University
    Journal
    Current Nanoscience, 2019, 15, 1-10
    		 Year
    2019
    Access
    Open

  4. Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products

    DOI Link
    Author
    Yue, C., et al.
    		 Organization
    Paul-Ehrlich-Institut, Asahi Kasei, Instituto Oswaldo Cruz
    Journal
    Viruses. 2019 Mar; 11(3): 234.
    		 Year
    2019
    Access
    Open

  5. Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration

    DOI Link
    Author
    Cetlin, D., et al
    		 Organization
    MockV Solutions, Inc.
    Journal
    Biotechnology Progress 34(5) pp.1113-1220
    		 Year
    2018
    Access
    Abstract Only

  6. Inactivation and removal of Zika virus during manufacture of plasma‐derived medicinal products

    DOI Link
    Author
    Blumel, J. et al
    		 Organization
    Paul-Ehrlich-Institut
    Journal
    Transfusion 2017 (57) 790-796
    		 Year
    2017
    Access
    Open

  7. cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidate

    DOI Link
    Author
    Dey, A., et al
    		 Organization
    International AIDS Vaccine Initiative, Department of Microbiology and Immunology, et al
    Journal
    Biotechnology and Bioengineering 2018 (115) 885–899
    		 Year
    2018
    Access
    Open

  8. Hepatitis E virus derived from different sources exhibits different behaviour in virus inactivation and/or removal studies with plasma derivatives

    DOI Link
    Author
    Yunoki, M., et al
    		 Organization
    Japan Blood Products Organization
    Journal
    Biologicals 44(5) 403-411
    		 Year
    2016
    Access
    Abstract Only

  9. Pathogen safety of a pasteurized four‐factor human prothrombin complex concentrate preparation using serial 20N virus filtration

    DOI Link
    Author
    Nowak, T., et al
    		 Organization
    CSL Behring
    Journal
    Transfusion 57(5) 1184-1191
    		 Year
    2017
    Access
    Open

  10. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid

    DOI Link
    Author
    Radomski, K., et al
    		 Organization
    Octapharma Biopharmaceuticals GmbH
    Journal
    BioDrugs (2017) 31: 125
    		 Year
    2017
    Access
    Open

  11. Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa

    DOI Link
    Author
    Ellgaard, T., et al
    		 Organization
    Novo Nordisk A/S
    Journal
    Protein Expression and Purification 129 (2017) 94-100
    		 Year
    2017
    Access
    Open

  12. Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein

    DOI Link
    Author
    McCue, J., et al
    		 Organization
    Biogen
    Journal
    Haemophilia 20(4): e327-e335
    		 Year
    2014
    Access
    Open

  13. BAY 81-8973, a full-length recombinant factor VIII: manufacturing processes and product characteristics

    DOI Link
    Author
    Garger, S., et al
    		 Organization
    Bayer
    Journal
    Haemophilia 23(2): e67-e78
    		 Year
    2017
    Access
    Open

  14. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein

    DOI Link
    Author
    McCue, J., et al
    		 Organization
    Biogen
    Journal
    Biologicals 43: 213–219
    		 Year
    2015
    Access
    Open

  15. Pathogen safety and characterisation of a highly purified human alpha1-proteinase inhibitor preparation

    DOI Link
    Author
    Kee, S., et al
    		 Organization
    CSL Behring
    Journal
    Biologicals 47: 25–32
    		 Year
    2017
    Access
    Open

  16. Validation and implementation of Planova™ BioEX virus filters in the manufacture of a new liquid intravenous immunoglobulin in China"

    DOI Link
    Author
    Ma, S., et al.
    		 Organization
    Shandong Taibang Biological Products Co., Ltd. and Asahi Kasei Medical Co., Ltd.
    Journal
    Biologicals 52 (2018) 37-43
    		 Year
    2018
    Access
    Abstract Only

  17. Characterizing the Impact of Pressure on Virus Filtration Processes and Establishing Design Spaces to Ensure Effective Parvovirus Removal

    DOI Link
    Author
    Strauss, D., et al
    		 Organization
    Asahi Kasei Bioprocess America
    Journal
    Biotechnology Process e-pub
    		 Year
    2017
    Access
    Open

  18. Effect of Hydrodynamic Forces on Virus Removal Capability of Planova™ Filters

    DOI Link
    Author
    Yamamoto,　A. et al.
    		 Organization
    Asahi Kasei Corporation
    Journal
    AIChE Journal Vol.60, No.6 2286-2297
    		 Year
    2014
    Access
    Abstract Only

  19. Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration

    DOI Link
    Author
    Maerz, H., et al.
    		 Organization
    University of Leipzig, Humboldt-University/Charite, Dr. Fooke Laboratorien GmbH, and Asahi Chemical Industries
    Journal
    Nature Biotechnology 14: 651-652
    		 Year
    1996
    Access
    No Abstract

  20. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq), a new generation recombinant factor VIII produced in a human cell-line

    DOI Link
    Author
    Winge, S., et al.
    		 Organization
    Octapharma AB
    Journal
    Protein Expression and Purification 115 (2015) 165–175
    		 Year
    2015
    Access
    Open
Next Page